Phase4 Ventures
11
65M
9
0.50
4
0.18
5
- Stages of investment
- Areas of investment
Summary
Phase4 Ventures is the famous VC, which was founded in 1999. The main department of described VC is located in the London. The company was established in Europe in United Kingdom.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Phase4 Ventures, startups are often financed by CMEA Ventures, Sofinnova Investments, Bay City Capital. The meaningful sponsors for the fund in investment in the same round are U.S. Venture Partners (USVP), ProQuest Investments, New Enterprise Associates. In the next rounds fund is usually obtained by Arax Capital Partners, New Enterprise Associates, MPM Capital.
Among the most popular portfolio startups of the fund, we may highlight Nabriva Therapeutics, Chroma Therapeutics, Phenomix. For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Consulting. The fund has exact preference in a number of founders of portfolio startups.
The important activity for fund was in 2007. The increased amount of exits for fund were in 2015. The common things for fund are deals in the range of 50 - 100 millions dollars. The real fund results show that this VC is 36 percentage points more often commits exit comparing to other companies. Comparing to the other companies, this Phase4 Ventures performs on 27 percentage points more the average number of lead investments. The fund is constantly included in less than 2 investment rounds annually. The typical startup value when the investment from Phase4 Ventures is 50-100 millions dollars.
Investments analytics
Analytics
- Total investments
- 11
- Lead investments
- 4
- Exits
- 5
- Rounds per year
- 0.50
- Follow on index
- 0.18
- Investments by industry
- Biotechnology (10)
- Pharmaceutical (7)
- Health Care (5)
- Therapeutics (3)
- Biopharma (3) Show 6 more
- Investments by region
-
- United States (9)
- Austria (1)
- United Kingdom (1)
- Peak activity year
- 2007
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 20
- Avg. valuation at time of investment
- 7M
- Group Appearance index
- 0.91
- Avg. company exit year
- 6
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Altus Pharmaceuticals | 26 May 2004 | Information Technology, Pharmaceutical, Data Center, Consulting | Late Stage Venture | 51M | United States, Ohio, Independence |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.